![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SY-307, a PRAME TCR/IL-15 NK based cell and gene therapy, is being investigated in patients with relapsed/refractory AML and MDS. It will be administered following lymphodepletion with standard doses of fludarabine/cyclophosphamide (Flu/Cy) and decitabine.
Lead Product(s): SY-307,Fludarabine Phosphate,Decitabine
Therapeutic Area: Oncology Product Name: SY-307
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy, which is being evaluated for the treatment of patients with relapsed or refractory multiple myeloma.
Lead Product(s): NY-ESO-1 TCR/IL-15,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: NY-ESO-1 TCR/IL-15
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syena
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
The collaboration aims to develop T cell receptor (TCR) based NK therapies in cancer by leveraging JURA Bio’s T cell receptor discovery platform to discover and develop innovative therapies by applying AI/machine learning.
Lead Product(s): T-cell Receptor Based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Jura Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 21, 2023
Details:
NY-ESO-1 TCR/IL-15 NKs are adoptive Natural Killer (NK) cells expressing an affinity-enhanced T-cell receptor (TCR) reactive directed against the NY-ESO-1-specific cord blood-derived NK cells.
Lead Product(s): NY-ESO-1 TCR/IL-15 NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
NY-ESO-1 TCR/IL-15 NK is an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.
Lead Product(s): NY-ESO-1 TCR/IL-15 NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
TCR-NK cell platform targets a selection of validated cancer neoantigens, including NY-ESO-1, and additional undisclosed TCRs. The NY-ESO-1 program in hematological malignancies and solid tumors.
Lead Product(s): TCR-NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Replay’s uCell™ platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (Induced Pluripotent Stem Cells) to be made immune silent.
Lead Product(s): iPSC-derived Immune Cell Therapy
Therapeutic Area: Oncology Product Name: uCell
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $1.5 million Upfront Cash: Undisclosed
Deal Type: Funding November 28, 2022
Details:
Telaria is the second of Replay’s four synHSV™ gene therapy product companies and its launch follows that of Eudora, a company targeting genetic diseases of the retina.
Lead Product(s): SynHSV Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: KKR
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 25, 2022